Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1993 Aug;143(2):401-9.

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

Affiliations

Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma

N Weidner et al. Am J Pathol. 1993 Aug.

Abstract

Tumor growth and metastasis require angiogenesis; and microvessel density, a measure of tumor angiogenesis, correlates with metastasis in breast and lung carcinoma. To determine how microvessel density correlated with metastasis in prostate carcinoma, we counted microvessels within the initial invasive carcinomas of 74 patients (29 with metastasis, 45 without). Microvessels were highlighted by immunostaining endothelial cells for factor VIII-related antigen. Without knowledge of the patient's cancer stage, microvessels were counted in a 200 field (0.739 mm2) in the most active areas of neovascularization. The mean microvessel count in tumors from patients with metastases was 76.8 microvessels per 200 field (median, 66; standard deviation, 44.6). The counts within carcinomas from patients without metastasis were significantly lower, 39.2 (median, 36; standard deviation, 18.6) (P < 0.0001). Microvessel counts increased with increasing Gleason's score (P < 0.0001), but this increase was present predominantly in the poorly differentiated tumors. Although Gleason's score also correlated with metastasis (P = 0.01), multivariate analysis showed that Gleason's score added no additional information to that provided by microvessel count alone. Assay of microvessel density within invasive tumors may prove valuable in selecting patients for aggressive adjuvant therapies in early prostate carcinoma.

PubMed Disclaimer

References

    1. J Exp Med. 1972 Aug 1;136(2):261-76 - PubMed
    1. J Pathol Bacteriol. 1954 Oct;68(2):603-16 - PubMed
    1. Cancer Res. 1976 Mar;36(3):889-94 - PubMed
    1. Adv Cancer Res. 1978;28:149-250 - PubMed
    1. Sci Am. 1979 Mar;240(3):66-76 - PubMed

LinkOut - more resources